Treatment of Concurrent Minimal Change Disease and Epstein Barr Virus–Driven Post-transplant Lymphoproliferative Disorder With Rituximab Following Hematopoietic Stem Cell Transplantation
Louise Ainley(University College Hospital), Ruth J. Pepper(University College Hospital), Manuel Rodriguez‐Justo(CRUK Lung Cancer Centre of Excellence), Steven Law(The Royal Free Hospital), Lauren Heptinstall(The Royal Free Hospital), Kirsty Thomson(University College Hospital)
Cited by 3
Related Papers
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
|Annals of the Rheumatic Diseases|2013|454
Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry
|Journal of Clinical Oncology|2011|216
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
|Journal of Clinical Oncology|2024|204
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
|Nephrology Dialysis Transplantation|2009|156